Y-931, a novel atypical antipsychotic drug, is less sensitive to oxidative phenomena

Chemical and Pharmaceutical Bulletin

Volumn 50, Issue 6, 2002, Pages 818-821

  Kohara, Toshiyuki ^a   Koyama, Toshiki ^b   Fujimura, Masatake ^a   Tanaka, Hiroshi ^a   Maeda, Junichi ^a   Fujimoto, Tetsuya ^b   Yamamoto, Iwao ^b   Arita, Masafumi ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b SHINSHU UNIVERSITY   (Japan)

Author keywords

Agranulocytosis; Clozapine; EPR; Olanzapine; Redox potential; Y 931

Indexed keywords

8 FLUORO 12 (4 METHYLPIPERAZIN 1 YL) 6H [1]BENZOTHIENO[2,3 B][1,5]BENZODIAZEPINE; CLOZAPINE; DRUG METABOLITE; NEUROLEPTIC AGENT; OLANZAPINE; UNCLASSIFIED DRUG; Y 931; 8 FLUORO 12 (4 METHYLPIPERAZIN 1 YL) 6H (1)BENZOTHIENO(2,3 B)(1,5)BENZODIAZEPINE; 8-FLUORO-12-(4-METHYLPIPERAZIN-1-YL)-6H-(1)BENZOTHIENO(2,3-B)(1,5)BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; GLUTATHIONE; HORSERADISH PEROXIDASE; HYDROGEN PEROXIDE; PIPERAZINE DERIVATIVE; PIRENZEPINE;

ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; ELECTRON SPIN RESONANCE; HUMAN; HUMAN CELL; LEUKOCYTE; NEUTROPHIL; OXIDATION REDUCTION POTENTIAL; SPIN TRAPPING; TOXICOKINETICS; DRUG EFFECT; DRUG STABILITY; METABOLISM; OXIDATION REDUCTION REACTION;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DRUG STABILITY; GLUTATHIONE; HORSERADISH PEROXIDASE; HUMANS; HYDROGEN PEROXIDE; NEUTROPHILS; OXIDATION-REDUCTION; PIPERAZINES; PIRENZEPINE;

EID: 0036597458     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.50.818     Document Type: Article

References (27)

1. Baldessarini R. J., Frankenburg F. R., N. Engl. J. Med., 324, 746-754 (1991).
2. Kane J., Honigfeld G., Singer J., Meltzer H., Arch. Gen. Psychiatry., 45, 789-796 (1988).
3. Alvir J. M. J., Lieberman J. A., J. Clin. Psychopharmacol., 14, 87-89 (1994).
4. Lieberman J. A., Safferman A. Z., Psychiatr. Q., 63, 51-70 (1992).
5. Lieberman J. A., Johns C. A., Kane J. M., Rai K., Pisciotta A. V., Saltz B. L., Howard A., J. Clin. Psychiatry., 49, 271-277 (1988).
6. Uetrecht J. P., Pharm. Res., 6, 265-273 (1989).
7. Beasley C. M., Tolletson G., Tran P., Satterlee W., Singer T., Hamilton S., Neuropsychopharmacology, 14, 111-123 (1996).
8. Fulton B., Goa K. L., Drugs, 53, 281-298 (1997).
9. Based on a lecture presented at 16th International Symposium on Medicinal Chemistry, Bologna, Italy, on 18-22 September, 2000.
10. Jardemark K. E., Ai J., Ninan I., Wang R. Y., Synapse, 41, 294-300 (2001).
11. Morimoto T., Hashimoto K., Yasumatsu H., Tanaka H., Fujimura M., Kuriyama M., Shoji H., Kimura K., Takehara S., Yamagami K., Neuropsychopharmacology, 26, 456-467 (2002).
12. Fischer V., Haar J. A., Greiner L., Lloyd R. V., Mason R. P., Mol. Pharmacol., 40, 846-853 (1991).
13. Liégeois J.-F., Mouithys-Mickalad A., Bruhwyler J., Delarge J., Petit C., Kauffmann J.-M., Lamy M., Biochem. Biophys. Res. Commun., 238, 252-255 (1997).
14. Green M. J., Hill H. A. O., "Methods in Enzymology," Vol. 105, ed. by Packer L., Academic Press, London, 1984, pp. 3-22.
15. Liu Z. C., Uetrecht J. P., J. Pharmacol. Exp. Ther., 275, 1476-1483 (1995).
16. Harman L. S., Carver D. K., Schreiber J., Mason R. P., J. Biol. Chem., 61, 1642-1648 (1986).
17. Gardner I., Zahid N., MacCrimmon D., Uetrecht J. P., Mol. Pharmacol., 53, 991-998 (1998).
18. Krupp P., Barnes P., Br. J. Psychiatry, 160, 38-40 (1992).
19. Liégeois J.-F., Rogister F., Delarge J., Pincemail J., Arch. Pharm., 328, 109-112 (1995).
20. Stock V. B., Spiteller G., Heipertz R., Arzneim.-Forsch., 27, 982-990 (1977).
21. Guillouzou A., Bégué J. M., Maurer G., Koch P., Xenobiotica., 18, 131-139 (1988).
22. Liégeois J.-F., Bruhwyler J., Petit C., Damas J., Delarge J., Géczy J., Kauffmann J.-M., Lamy M., Meltzer H., Mouithys-Mickalad A., Arch. Biochem. Biophys., 370, 126-137 (1999).
23. Fulton B., Goa K. L., Drugs, 53, 281-298 (1997).
24. Aravagiri K., Ames D., Wirshing W. C., Marder S. R., Ther. Drug Monit., 19, 307-313 (1997).
25. Weigmann H., Hiemke C., J. Chromatogr., 583, 209-216 (1992).
26. Laidlaw S. T., Snowden J. A., Brown M. J., Lancet, 342, 1245 (1993).
27. Philpott N. J., Marsh J. C., Gordon-Smith E. C., Lancet, 342, 1244-1245 (1993).